Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis

Nephrology Dialysis Transplantation

Volumn 22, Issue 6, 2007, Pages 1703-1708

  Montenegro, Jesús ^a   Saracho, Ramón ^a   Gallardo, Isabel ^a   Martñnez, Isabel ^a   Muñoz, Rosa ^a   Quintanilla, Nuria ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Bicarbonate solution; Biocompatibility of peritoneal solutions; Peritoneal dialysis; Peritonitis

Indexed keywords

BUFFER; GLUCOSE DEGRADATION PRODUCT; LACTIC ACID;

ADULT; AGED; ARTICLE; BIOCOMPATIBILITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; GLOMERULONEPHRITIS; GRAM POSITIVE BACTERIUM; HUMAN; INCIDENCE; INTERSTITIAL NEPHRITIS; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROFLORA; MYCOSIS; OBSERVATIONAL STUDY; OPEN STUDY; OROPHARYNX; PERITONITIS; PH; PRIORITY JOURNAL; TREATMENT DURATION;

BICARBONATES; BUFFERS; DIALYSIS SOLUTIONS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS; PROSPECTIVE STUDIES;

EID: 34447578047     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl848     Document Type: Article

References (24)

1. Daly CD, Campbell MK, MacLeod AM et al. Do the T-set and double-bag systems reduce the incidence of CAPD peritonitis? Nephrol Dial Transplant 2001; 16: 341-347
2. Kiernan L, Kliger A, Gorban-Brennan N et al. Comparison of continuous ambulatory peritoneal dialysis-related infections with different "T-tubing" exchange systems. J Am Soc Nephrol 1995; 5: 1835-1838
3. Schaubel DE, Blake PG, Fenton SSA. Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. Kidney Int 2001: 60: 1517-1524
4. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506
5. De Vriese AS, Mortier S, Lameire NH. Neoangiogenesis in the peritoneal membrane: Does it play a role in ultrafiltration failure? Nephrol Dial Transplant 2001; 16: 2143-2145
6. Rippe B, Simonsen O, Heimburger O et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348-357
7. Liberek T, Topley N, Jorrers A et al. Peritoneal dialysis fluid inhibition of phagocyte function: Effects of osmolality and glucose concentration. J Am Soc Nephrol 1993; 3: 1508-1515
8. Witowski J, Wisniewska J, Korybalska K et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12: 2434-2441
9. Woodrow G. Can biocompatible dialysis fluids improve outcomes in peritoneal dialysis patients? Perit Dial Int 2005; 25: 230-233
10. Feriani M, Kirchgessner J, La Greca G et al. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54: 1731-1738
11. Coles GA, Gokal R, Ogg G et al. A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 1997; 17: 48-51
12. Mortier S, De Vriese AS, McLoughlin RM et al. Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol 2003; 14: 1296-1306
13. Jorres A, Bender TO, Finn A et al. Biocompatibility and buffers: effect of bicarbonate-buffered peritoneal dialysis fluids on peritoneal cell function. Kidney Int 54: 2184-2193
14. Boulanger E, Wautier MP, Wautier JL et al. AEGs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002; 61: 148-156
15. Mackenzie R, Holmes CJ, Jones S et al. Clinical indices of in vivo biocompatibility: The role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney Int 2003; 64 [Suppl]: S84-S93
16. Montenegro J, Saracho R, Aguirre R et al. Exit-site care with ciprofloxacin otologic solution prevents polyurethane catheter infection in peritoneal dialysis patients. Perit Dial Int 2000; 20: 209-214
17. Piraino P, Bailie GR, Bernardini J et al. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005; 25: 107-131
18. Williams JD, Topley N, Craig KJ et al. The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66: 408-418
19. Montenegro J, Saracho RM, Martinez IM et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26: 89-94
20. Amato D, de Jesus Ventura M, Miranda G et al. Staphylococcal peritonitis in continuous ambulatory peritoneal dialysis: Colonization with identical strains at exit site, nose, and hands. Am J Kidney Dis 2001; 37: 43-48
21. Fusshoeller A, Plail M, Grabensee B et al. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: A prospective, randomized study. Nephrol Dial Transplant 2004; 19: 2101-2106
22. Puig-Kroger A, Muniz-Pello O, Selgas R et al. Peritoneal dialysis solutions inhibit the differentiation and maturation of human monocyte-derived dendritic cells: Effect of lactate and glucose-degradation products. J Leukoc Biol 2003; 73: 482-492
23. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-523
24. Lee HY, Park HC, Seo BJ et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-255